ES2175089T3 - Una combinacion de un inhibidor de la absorcion de 5 - ht con un ant agonista selectivo de 5 ht1a. - Google Patents

Una combinacion de un inhibidor de la absorcion de 5 - ht con un ant agonista selectivo de 5 ht1a.

Info

Publication number
ES2175089T3
ES2175089T3 ES96912370T ES96912370T ES2175089T3 ES 2175089 T3 ES2175089 T3 ES 2175089T3 ES 96912370 T ES96912370 T ES 96912370T ES 96912370 T ES96912370 T ES 96912370T ES 2175089 T3 ES2175089 T3 ES 2175089T3
Authority
ES
Spain
Prior art keywords
combination
selective
ht1a
sub
absorption inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96912370T
Other languages
English (en)
Inventor
John Evenden
Seth-Olov Thorberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of ES2175089T3 publication Critical patent/ES2175089T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA INVENCION SE REFIERE A UNA COMBINACION DE UN PRIMER COMPONENTE (A) QUE ES UN INHIBIDOR DE LA RECAPTACION DE 5 UN SEGUNDO COMPONENTE (B) QUE ES UN ANTAGONISTA SELECTIVO DE 5 ROPILO O CICLOBUTILO; R SUB,2} ES ISOPROPILO, BUTILO TERCIARIO, CICLOBUTILO, CICLOPENTILO O CICLOHEXILO; R SUB,3} ES HIDROGENO; R SUB,4} ES HIDROGENO O METILO; COMO EL ENANTIOMERO (R) EN FORMA DE LA BASE LIBRE O DE SALES FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS, A LA PREPARACION DE LOS MISMOS, A LAS FORMULACIONES FARMACEUTICAS QUE CONTIENEN DICHA COMBINACION, AL USO DE Y A UN METODO PARA EL TRATAMIENTO DE TRASTORNOS DE LA AFECTIVIDAD TALES COMO DEPRESION, ANSIEDAD Y OCD CON DICHA COMBINACION, ASI COMO UN KIT QUE CONTIENE DICHA COMBINACION.
ES96912370T 1995-04-27 1996-04-23 Una combinacion de un inhibidor de la absorcion de 5 - ht con un ant agonista selectivo de 5 ht1a. Expired - Lifetime ES2175089T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9501567A SE9501567D0 (sv) 1995-04-27 1995-04-27 A new combination

Publications (1)

Publication Number Publication Date
ES2175089T3 true ES2175089T3 (es) 2002-11-16

Family

ID=20398119

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96912370T Expired - Lifetime ES2175089T3 (es) 1995-04-27 1996-04-23 Una combinacion de un inhibidor de la absorcion de 5 - ht con un ant agonista selectivo de 5 ht1a.

Country Status (30)

Country Link
US (5) US5962514A (es)
EP (1) EP0822813B1 (es)
JP (1) JPH11504037A (es)
KR (1) KR100419810B1 (es)
CN (1) CN1102386C (es)
AR (1) AR002990A1 (es)
AT (1) ATE216579T1 (es)
BR (1) BR9608252A (es)
CA (1) CA2218181A1 (es)
CZ (1) CZ335697A3 (es)
DE (1) DE69620878T2 (es)
DK (1) DK0822813T3 (es)
EE (1) EE03553B1 (es)
ES (1) ES2175089T3 (es)
HK (1) HK1002853A1 (es)
HU (1) HUP9801946A3 (es)
IL (1) IL117988A0 (es)
IS (1) IS1821B (es)
NO (1) NO317057B1 (es)
NZ (1) NZ306602A (es)
PL (1) PL183997B1 (es)
PT (1) PT822813E (es)
RU (1) RU2183955C2 (es)
SE (1) SE9501567D0 (es)
SK (1) SK282060B6 (es)
TR (1) TR199701254T1 (es)
TW (1) TW458777B (es)
WO (1) WO1996033710A1 (es)
YU (1) YU25696A (es)
ZA (1) ZA962982B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9501567D0 (sv) * 1995-04-27 1995-04-27 Astra Ab A new combination
SE9703374D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination
WO1999061014A2 (en) * 1998-05-28 1999-12-02 Sepracor Inc. Compositions and methods employing r(-) fluoxetine and other active ingredients
SE9803156D0 (sv) * 1998-09-16 1998-09-16 Astra Ab A new composition
SE9803157D0 (sv) * 1998-09-16 1998-09-16 Astra Ab A new composition
SE9803158D0 (sv) * 1998-09-16 1998-09-16 Astra Ab A new composition
SE9803155D0 (sv) * 1998-09-16 1998-09-16 Astra Ab A new composition
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
US6331233B1 (en) 2000-02-02 2001-12-18 Honeywell International Inc. Tantalum sputtering target with fine grains and uniform texture and method of manufacture
AU9543601A (en) 2000-10-13 2002-04-22 Neurosearch As Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance
US20030166554A1 (en) * 2001-01-16 2003-09-04 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
US20030185754A1 (en) * 2001-01-16 2003-10-02 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
PL367480A1 (en) * 2001-05-01 2005-02-21 H.Lundbeck A/S The use of enantiomeric pure escitalopram
US7034059B2 (en) 2001-07-02 2006-04-25 Sepracor Inc. Methods of using norfluoxetine
US6855735B2 (en) 2002-03-20 2005-02-15 Temple University Of The Commonwealth System Of Higher Education Ketamine treatment of restless legs syndrome
AU2003256430A1 (en) * 2002-08-15 2004-03-03 Wyeth AGONISM OF THE 5HT2a RECEPTOR FOR TREATMENT OF THERMOREGULATORY DYSFUNCTION
US20050032873A1 (en) * 2003-07-30 2005-02-10 Wyeth 3-Amino chroman and 2-amino tetralin derivatives
US7695601B2 (en) * 2006-05-09 2010-04-13 The United States Of America As Represented By The Secretary Of The Army Electrochemical test apparatus and method for its use
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
US20160154928A1 (en) * 2013-07-12 2016-06-02 Immuneering Corporation Systems, methods, and environment for automated review of genomic data to identify downregulated and/or upregulated gene expression indicative of a disease or condition
JP7153653B2 (ja) 2017-02-14 2022-10-14 リサーチ トライアングル インスティテュート プロリン系神経ペプチドｆｆ受容体モジュレーター

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4698342A (en) * 1985-07-16 1987-10-06 Serotonin Industries Of Charleston Method and compositions for controlling pain, depression and sedation
US5616610A (en) * 1989-12-22 1997-04-01 Astra Aktiebolag (R)-5-carbamoyl-8-fluoro-3-N,N-disubstituted-amino-3,4-dihydro-2H-1-benzopyrans
US5420151A (en) * 1989-12-22 1995-05-30 Aktiebolaget Astra Chroman derivatives
SE9501567D0 (sv) * 1995-04-27 1995-04-27 Astra Ab A new combination

Also Published As

Publication number Publication date
CA2218181A1 (en) 1996-10-31
IS1821B (is) 2002-08-27
DE69620878D1 (de) 2002-05-29
IS4585A (is) 1997-10-09
US5962514A (en) 1999-10-05
KR19990008068A (ko) 1999-01-25
ZA962982B (en) 1996-10-28
US6172105B1 (en) 2001-01-09
CN1102386C (zh) 2003-03-05
CZ335697A3 (cs) 1998-06-17
NO317057B1 (no) 2004-08-02
BR9608252A (pt) 1999-05-04
ATE216579T1 (de) 2002-05-15
SK282060B6 (sk) 2001-10-08
EE9700245A (et) 1998-04-15
RU2183955C2 (ru) 2002-06-27
TR199701254T1 (xx) 1998-02-21
IL117988A0 (en) 1996-08-04
AR002990A1 (es) 1998-05-27
EP0822813B1 (en) 2002-04-24
DK0822813T3 (da) 2002-07-29
DE69620878T2 (de) 2002-11-14
SK142997A3 (en) 1998-12-02
EP0822813A1 (en) 1998-02-11
CN1187768A (zh) 1998-07-15
EE03553B1 (et) 2001-12-17
HUP9801946A2 (hu) 2000-05-28
US6184219B1 (en) 2001-02-06
PL183997B1 (pl) 2002-08-30
AU5520296A (en) 1996-11-18
NZ306602A (en) 1999-04-29
NO974921D0 (no) 1997-10-24
AU696356B2 (en) 1998-09-10
NO974921L (no) 1997-12-18
TW458777B (en) 2001-10-11
HK1002853A1 (en) 1998-09-25
KR100419810B1 (ko) 2004-04-21
PT822813E (pt) 2002-10-31
US6184218B1 (en) 2001-02-06
US6169098B1 (en) 2001-01-02
SE9501567D0 (sv) 1995-04-27
PL323083A1 (en) 1998-03-02
YU25696A (sh) 1999-06-15
JPH11504037A (ja) 1999-04-06
HUP9801946A3 (en) 2000-12-28
WO1996033710A1 (en) 1996-10-31

Similar Documents

Publication Publication Date Title
ES2175089T3 (es) Una combinacion de un inhibidor de la absorcion de 5 - ht con un ant agonista selectivo de 5 ht1a.
UY28026A1 (es) 4-piperazinilbencenosulfonilindoles y usos de los mismos.
GT199900040A (es) Biciclo [2.2.1] heptanos y compuestos relacionados.
UY26797A1 (es) Derivados de purina
PA8546601A1 (es) Nuevos derivados de indol con afinidad por el receptor 5-ht6
ES2159738T3 (es) Derivados de benzamida y su uso como antagonistas de vasopresina.
UY24986A1 (es) Compuestos
HN1998000157A (es) Agonistas de prostaglandinas
HN1999000149A (es) Derivados de 4,4-biarilpiperidina
UY26819A1 (es) Derivados de pirazol
PA8536001A1 (es) Derivados de quinazolona como antagonistas de receptores adrenérgicos alfa-1a/b
SV2003000633A (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7
GT200100153A (es) Compuestos de 1,4-dihidropiridina como antagonistas de bradiquinina.
AR015448A1 (es) COMBINACIoN DE UN INHIBIDOR DE REABSORCIoN DE 5-HT CON UN ANTAGONISTA O AGONISTA PARCIAL DE H5-HT1B, PROCESO PARA SU PREPARACIoN, FORMULACIoN FARMACÉUTICA QUE LA CONTIENE, SU USO PARA PREPARAR MEDICAMENTOS PARA TRATAR TRASTORNOS AFECTIVOS Y KIT QUE CONTIENE DICHA COMBINACIoN
ES2190205T3 (es) Combinacion para el tratamiento de la dependencia del alcohol que contiene un antagonista opioide y un modulador del complejo receptor de nmda.
AR018162A1 (es) Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica
ECSP034531A (es) Derivados sustituidos de c-ciclohexilmetilamina
HN2001000235A (es) Derivados puentes de piperazina
UY27203A1 (es) Bencimidazoles útiles en el tratamiento de la disfunción sexual
ES2171911T3 (es) Poliaminas conformacionalmente restringidas y su uso como agentes antineoplasicos.
BR0214649A (pt) Derivados de aminotetralina como antagonistas do receptor muscarìnico
AR004691A1 (es) Nuevos derivados de [3-alcoxi-fenoxi-)-etil]-dialquilamina, una composicion farmaceutica que los comprende, su uso como anestesicos locales y unprocedimiento para su preparacion
ECSP034530A (es) Derivados de 6-metil-tramadol sustituido en o
ES2145563T3 (es) Nuevos derivados de la imidazolina con una afinidad para los receptores imidazolinicos.
ES2189072T3 (es) Nuevo benzo-cicloalquenos heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 822813

Country of ref document: ES